<DOC>
	<DOCNO>NCT02107846</DOCNO>
	<brief_summary>This open-label , dose escalation study evaluate safety oral PRX-112 pharmacokinetics GCD subject Gaucher disease naive enzyme replacement therapy . The dose level PRX-112 50 unit , 100 unit , 200 unit 400 unit GCD . Subjects receive daily oral administration PRX-112 5 consecutive day dose level 2-day washout period dos .</brief_summary>
	<brief_title>An Open-Label , Dose Escalation Study Evaluate Safety Pharmacokinetics Oral PRX-112</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Male female age 18 old Historical diagnosis Gaucher disease low leukocyte GCD activity level Haemoglobin ≥ 10 g/dL Body mass index ( BMI ) 18 kg/m230 kg/m2 inclusive Subject able provide write informed consent Female subject child bear potential must pregnant lactate negative urine pregnancy test result screen visit . Female subject childbearing potential male subject female partner childbearing potential must use two method contraception time study , one must barrier method . Acceptable method contraception oral contraceptive , barrier method ( male condom , female condom , diaphragm , cervical cap , spermicide intrauterine device ) , surgical sterility ( documented doctor 's report vasectomy , hysterectomy and/or bilateral oophorectomy ) and/or postmenopausal status ( define least 1 year without menses demonstrate medical history subject report ) . Negative laboratory test HIV , HBsAg HCV screen visit Naïve previous ERT receive last ERT treatment 12 month sign IC Presence gastrointestinal ( GI ) disease affect motility absorption Subjects history allergic response biological drug allergy deem clinically significant Investigator Reported history alcohol drug abuse Subject donate blood 3 month prior screen subject receive plasma derivative 6 month prior screen Use investigational drug participation another clinical trial 3 month prior screen ( subject report ) Subjects previously receive ERT positive antihuman plant recombinant GCD ( prGCD ) antibodies Clinical evidence active significant disease could potentially compromise ability Investigator evaluate interpret effect study treatment safety assessment , thus increase risk subject unacceptable level Presence medical , emotional , behavioural psychological condition , judgement Investigator , would interfere compliance requirement study Subject use medication ( exclude acetaminophen dyprione ) within 7 day screen , include laxative , tea food additive know used treatment constipation diarrhea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>